

SAMORITA HOSPITAL LIMITED
First Quarter Financial Statements

Dear Shareholders,

We are pleased to forward herewith the unaudited Financial Statements of the company for the first quarter ended 30th September, 2024 as per Bangladesh Securities and Exchange Commission's notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

Statement of Financial Position (Un-audited)
As at 30 September, 2024 (Figure in Taka "000")

Particular	Notes	September, 30 2024	June, 30 2024
Assets			
Non-Current Assets			
Property, Plant & Equipment(WDV)	3	1,098,408	1,099,741
Right of Use Assets	4	399	798
Investment in Associate	5	5,993	5,985
Total Non-Current Assets		1,104,800	1,106,524
Current Assets:			
Inventories	6	19,478	20,029
Trade Receivable	7	9,900	9,331
Advance, Deposits & Prepayments	8	8,171	11,204
Advance Income Tax	9	16,266	16,207
Cash & Cash Equivalents	10	48,789	49,447
Other Assets	10.01	6,928	3,297
Total Current Assets		109,532	109,515
Total Assets		1,214,332	1,216,039
Equity and Liabilities			
Shareholders' Equity:			
Share Capital	11	218,009	218,009
Retained Earnings	12	118,052	112,880
Revaluation Reserve	14	717,969	717,969
Dividend Equalisation Fund	13	3,837	3,565
Total Equity		1,057,868	1,052,423
Non-Current Liabilities :			
Deferred Tax Liabilities	15	81,149	84,953
Long Term Loan	17	261	261
Total Non-Current Liabilities		81,410	85,214
Current Liabilities :			
Trade Payable	18	32,744	34,515
Long Term Loan (Current Portion)	19	16,800	21,480
Lease Liability- current portion	16.01	450	890
Other Payable	20	2,764	791
Provision & Accruals	21	11,590	10,975
Provision for Income Taxes	22	9,429	8,472
Unclaimed Dividend	23	1,279	1,279
Total Current Liabilities		75,055	78,402
Total Liabilities		156,465	163,616
Total Equity and Liabilities		1,214,332	1,216,039

Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the first quarter ended 30th September, 2024. (Figure in Taka "000")

	Notes	July, 2024 to September, 2024	July, 2023 to September, 2023
Revenue	25	96,132	119,347
Direct Expenses	26	(40,939)	(43,201)
Gross Profit		55,193	76,146
Operating Expenses:			
Administrative Expenses	27	(52,879)	(52,051)
Profit from Operation		2,314	24,095
Share of Profit/ (loss) of Associate	24	8	20
Financial Expenses	28	(704)	(998)
Non Operating Income	29	1,110	1,466
Profit before contribution to WPPF		2,728	24,583
Contribution to WPPF		(130)	(1,171)
Profit Before Tax		2,598	23,411
Income Tax Expenses		2,847	(5,176)
Current Tax	30	957	5,782
Deferred Tax	15.01	(3,804)	(606)
Profit after Tax		5,445	18,236
Total Comprehensive income		5,445	18,236
EPS		0.25	0.84


C F O


Company Secretary


Managing Director


Director


Chairman

Statement of Changes In Equity (Un-audited)
For the first quarter ended 30th September , 2024. (Figure in Taka "000")

Particular	Share Capital	Retained Earning	Dividend Equalisation Fund	Revaluation Reserve	Total
Balance as at July 01,2024	218,009	112,880	3,565	717,969	1,052,423
Total Comprehensive income	-	5,445	-	-	5,445
Transferred to Dividend Equalisation Fund	-	(272)	272	-	-
Revaluation Surplus on land	-	-	-	-	-
Transferred to deferred tax liabilities	-	-	-	-	-
Balance as at September 30,2024	218,009	118,052	3,837	717,969	1,057,868
Balance as at July 01,2023	198,190	121,110	2,955	636,826	959,081
Total Comprehensive income	-	18,236	-	-	18,236
Transferred to Dividend Equalisation Fund	-	-	-	-	-
Revaluation Surplus on land	-	-	-	124,099	124,099
Transferred to deferred tax liabilities	-	-	-	(7,582)	(7,582)
Balance as at September 30,2023	198,190	139,346	2,955	753,343	1,093,835

Statement of Cash Flows (Un-audited)
For the first quarter ended 30th September , 2024. (Figure in Taka"000")

	September,30 2024	September,30 2023
A. Cash flows from Operating Activities:		
Cash Received from Customers	96,735	116,938
Cash Paid to Suppliers & Employees	(85,146)	(77,039)
Cash generated from Operations:	11,589	39,899
Income Tax Paid	(60)	(125)
Net Cash from Operating Activities	11,529	39,774
B. Cash flows from Investing Activities		
Purchase of Property, Plant & Equipment	(3,259)	(6,505)
Other Assets	(3,632)	-
FDR interest	74	438
Net Cash used in Investing Activities	(6,817)	(6,067)
C. Cash flows from Financing Activities		
Bank Loan paid	(5,370)	(5,455)
Unclaimed Dividend	-	271
Net Cash Used in Financing Activities	(5,370)	(5,184)
D. Net Cash Inflows / (outflows)	(658)	28,523
E. Opening Cash & Bank Balance	49,447	44,366
F. Closing Cash & Bank Balance	48,789	72,889

Additional information as per listing regulation:

Particulars	September,30 2024	June,30 2024
Net Assets Value per Share (NAV)	48.52	48.27
Earning Per Share(EPS)	0.25	0.84
Net Operating Cash Flow Per Share(NOCFPS)	0.53	1.82

Reasons of deviation in financial parameters:

Operating results:

Operating result in the reporting period has been significantly decreased due to the following reasons, compared to previous corresponding period:

- Revenue has been decreased by Tk. 2.32 Crore.
- Cost of direct materials has been increased by 6.39%.
- Operating expenses to revenue has been increased from 43.61% to 55.01% .

Net operating cash flow per share (NOCFPS) decreased from Tk. 1.82 to Tk.0.53 due to cash receipts from customers have been decreased by Tk. 2.02 Crore.




C F O



Company Secretary



Managing Director



Director



Chairman

"The details of the published first quarter financial statements can be available in the web-site of the company. The address of the web-site is www.samoritahospital.org "

Samorita Hospital Limited
Selected Notes to the Financial Statements(Un-audited)
For the first quarter ended 30th September , 2024

1.00 Legal status and nature of the Company-Disclosure under IAS-1 "Presentation of Financial Statements".

1.01 Company Profile

Samorita Hospital Limited started its business from 01 February 1984 under the name and style as "M/s. Samorita Nursing Home". Then it was a partnership concern and 14 October 1985 it was converted into a Private Limited Company under the name and style as Samorita Nursing Home Ltd. Subsequently its name and style was changed and renamed as Samorita Hospital (Pvt.) Limited on 17 January 1990. Again on 23 June 1996 it was converted into a Public Limited Company under the name and style as "Samorita Hospital Limited".

The company went for public issue of share in 1996 and its shares are listed with the Stock Exchanges of Bangladesh.

1.02 Basis of preparation of Financial Statements:

These interim Financial Statements should be read in conjunction with the financial statements for the year ended 30th June, 2024 as they provide an update to previously reported information.

The Accounting Policies used are consistent with those in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRS). The Presentation of the interim Financial Statements is consistent with the Annual Financial Statements.

1.03 Investment in associate Company:

The Company's investment in associate company is accounted for in the financial statements using the Equity Method in accordance with IAS-28 "Investment in Associates".

2.00 Specific Accounting Policies selected and applied for Significant Transactions and Events:

2.01 Accounting Convention (Measurement IASs)

The financial statements have been prepared on a going concern basis under the historical cost convention in accordance with International Financial Reporting Standards (IFRSs) therefore, do not take into consideration the effect of inflation.

2.02 Statement of compliance

The financial statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRSs), and The Companies Act 1994 and Securities & Exchange Rules 2020.

2.03 Reporting Currency and Level of Precision

The financial statements are presented in Bangladeshi Taka (BDT) which is the functional currency of the company. The amounts in these financial statements have been rounded off to the nearest integer.

2.04 Risk and Uncertainties for use of estimates in preparation of Financial Statements

The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. Actual result could differ from those estimates. Estimates are used for accounting certain items such as long term contract, provision for doubtful contracts, depreciation and amortization, Tax reserve and contingencies.

2.05 Reporting Period

The company's accounting year is July-June and this financial statements are prepared covering the period of three month from 01 July 2024 to 30 September 2024.

2.06 Comparative Information

Comparative information has been disclosed in respect of the period in accordance with IAS-1: Presentation of Financial Statements, for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

2.07 Recognition of Property, Plant & Equipment and Depreciation

Property, plant & equipment are recognized if it is probable that future economic benefits associated with the assets will flow to the company and the cost of the assets can be reliably measured. All fixed assets are stated at cost or revaluation less accumulated depreciation as per IAS-16 "Property, Plant and Equipment". No depreciation is charged on land and land development. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes. The cost and accumulated depreciation of depreciable assets retired or otherwise disposed of are subject to elimination from the assets and accumulated depreciation and any gain or loss on such disposal will reflect in operations for the period.

2.08 Revaluation of Freehold Land

Samorita Hospital Limited revalued the freehold land on 30th September, 2023 by Basu Banerjee Nath & Co. a Chartered Accountancy firm and the details of the revaluation of Freehold Land of the Company as under:

Area of Land (Decimal)	Cost	Revaluation gain (As per revaluation of the year 2013)	Book value as on 30th June,2022	Current value as per revaluation on 30th Sept, 2023.	Revaluation gain 2023-2024
28.66	30,182,041	664,617,959	694,800,000	706,357,727	11,557,727
3.60	33,079,000	-	33,079,000	62,021,477	28,942,477
6.80	32,367,190	-	32,367,190	115,965,682	83,598,492
39.06	95,628,231	664,617,959	760,246,190	884,344,886	124,098,696

The Board of Directors adopted the valuation report in its 203rd meeting held on October 28, 2023 unanimously.

2.09 Inventories

Inventories comprise various Medicine, Material for Pathology, X-Ray, OT, Cleaning Materials, Linens, Printing and Stationery, Materials for ECG and USG. They are stated at the lower of cost and net realizable value in accordance with IAS -2 "Inventories" after making due allowances for any obsolete or slow moving items.

2.10 Financial Instruments

Financial Assets

Trade Receivable

Trade receivables are recognized and stated at original invoiced amounts and carried at anticipated realizable values.

Cash and Cash Equivalent

It includes cash in hand and cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

2.11 Creditors and Accrued Expenses

Liabilities are recognized for amounts to be paid in future for goods and services received, whether or not billed by the supplier.

2.12 Taxation

Income tax expenses comprise current and deferred taxes. Income taxes are recognized in statement of profit or loss and other comprehensive income except to the extent that relates to items recognized directly in equity or in other comprehensive income. The Company is a publicly traded Company. As per the Income Tax Act 2023, provision for Tax has been made at the existing rate of 22.50% in respect of business income.

Current Tax

Provision for current income tax has been made as per prescribed rate in the Finance Act, 2023 on the accounting profit made by the company after considering some of the add backs to income and disallowances of expenditure as per income tax laws in compliance with IAS-12: "Income Taxes".

Deferred Tax

Deferred tax liabilities are the amount of income taxes payable in future periods in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future periods in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax bases. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities has also been recognized in the statement of comprehensive income as per IAS-12: "Income Taxes".

2.13 Revenue Recognition

In accordance with the provisions of the IFRS-15: "Revenue from Contracts with Customers"; revenue from contracts with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue has been recognized at the time of invoice made for the services rendered by the company.

Interest income

The interest income is recognized on accrual basis as agreed terms and conditions with the banks.

Non operating income

Non operating income are recognized at the time of receive of money from other purpose than the normal course of business of the Company.

2.14 Earnings Per Share (EPS)

The Company calculates Earnings Per Share (EPS) in accordance with IAS -33 "Earnings Per Share", which has been shown on the face of the statement of comprehensive income. This has been calculated by dividing the basic earnings by the number of ordinary shares outstanding during the year.

2.15 Statement of Cash Flows

Statement of Cash Flows is prepared principally in accordance with IAS -7 "Statement of Cash Flows" and the cash flow from the operating activities have been presented under the direct method as prescribed by the Securities and Exchange Rules 1987 and considering the provision of Paragraph 19 of IAS -7 which provides that enterprise are encouraged to report "Cash Flow from the Operating Activities using the direct Method".

2.16 Additional information on Financial Statements:

Compliance with International Financial Reporting Standards (IFRSs)

The financial statements have been prepared in compliance with requirements of IFRSs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

2.17 Foreign Exchange Earned and Payment

During the period the Company has not earned or made payment any amount of foreign currency.

2.18 Provisions, Contingent Liabilities and Contingent Assets (IAS-37)

There are certain pending tax claims made against the Company, which will be settled through the legal process in due course. These are being vigorously defended by the company. The management has not considered it necessary at the reporting date to make provisions in the financial statements in respect of any of these claims.

Accounting Year	Assessment Year	Tax Declared	Assessment by Tribunal	Tax paid	Tax Liability/ Claimed Amount	Present Status
2012-2013	2013-2014	13,623,217	12,843,912	13,723,217	(879,305)	Case has been remanded to tax Appellate Tribunal

2013-2014	2014-2015	11,669,566	15,188,234	12,879,566	2,308,668	Case has been remanded to tax Appellate Tribunal
2014-2015	2015-2016	11,473,176	12,616,428	11,773,176	843,252	Case has been remanded to tax Appellate Tribunal
2015-2016	2016-2017	10,372,742	12,904,058	11,482,742	1,421,316	Case has been remanded to tax Appellate Tribunal
2016-2017	2017-2018	13,918,465	14,450,494	14,433,465	17,029	Case has been remanded to tax Appellate Tribunal
2017-2018	2018-2019	8,675,427	8,893,836	9,747,897	(854,061)	-
2018-2019	2019-2020	11,453,108	-	11,453,108	-	Return Submitted Under Section 82BB
2019-2020	2020-2021	3,678,790	13,143,637	9,329,484	3,814,153	Case is Pending at Tax Appellate Tribunal
2020-2021	2021-2022	13,632,068	15,316,074	11,717,130	3,598,944	Case is Pending at Tax Appellate Tribunal
2021-2022	2022-2023	5,154,507	-	6,287,425	(1,132,918)	Return Submitted but Assessment not yet done
2022-2023	2023-2024	2,650,892	-	2,876,214	(225,322)	Return Submitted Under Section 180
Total		106,301,958	105,356,673	115,703,424	8,911,756	

2.19 Impairment of Assets (IAS-36)

No facts and circumstances indicate that the company's assets may be impaired. Hence, no evaluation of recoverability of assets was performed.

2.20 Employee Benefits (IAS-19)

The Company provides short term employee benefits to its eligible employees in the form of incentive which charged as revenue expenditure in the period to which the incentive relates.

2.21 Workers' Profit Participation and Welfare Fund:

The Company recognizes a provision for Workers' Profit Participation Fund @ 5% of net profit before Taxes in accordance with Bangladesh Labour Law 2006.

**As at
September, 30
2024**

**As at
June, 30
2024**

Figure in Taka"000"

3. Property, Plant & Equipment:

Cost/Revaluation:

Land	884,346	884,345
Building	254,281	254,281
Equipments	186,941	182,877
Furniture & Fixture	29,981	29,868
Lift	18,735	18,735
Generator	7,630	7,630
Medical Oxygen System	30,083	30,083
Others	42,780	42,699

1,454,777

1,450,518

Less: Accumulated Depreciation

Written Down Value

356,369

350,777

1,098,408

1,099,741

4.Right of Use Assets

Cost	4,790	4,790
Less: Amortisation	4,391	3,992
	399	798

5. Investment in Associate:

Opening Balance	5,985	5,944
Share of income / (loss) of Associate (note.24)	8	41
	5,993	5,985

Share of income of Associate has been shown on the basis of unaudited report of the Imaging services Ltd. (Associate company) for the 1st quarter ended september 30 , 2024 in accordance with IAS-28.

	As at September, 30 2024	As at June, 30 2024
Figure in Taka"000"		
6. Inventories:		
Medical Services	4,326	4,224
Diagnostics	2,493	3,915
Pharmacy	12,659	11,890
	19,478	20,029
7. Trade Receivable:		
Receivable from Indoor Patient	5,599	5,443
Receivable from Outdoor Patient	1,044	908
Receivable from Institution	2,925	2,663
Rent Receivable	332	290
Receivable from FDR Interest	-	27
	9,900	9,331
8. Advance, Deposits & Prepayments :		
Advance for Work & others	1,105	1,972
Security Money & Deposit	1,538	1,538
Prepayments	5,528	7,694
	8,171	11,204
9. Advance Income Tax		
Opening Balance	16,207	13,528
Add: Paid during the year	59	5,330
	16,266	18,858
Less: Adjusted during the year	-	2,651
Closing Balance	16,266	16,207
10. Cash & Cash Equivalents :		
Cash in hand	913	670
Cash at bank	47,876	48,777
	48,789	49,447
10.01 Other Assets:		
Cash in bank	6,928	3,297

Considering the present situation of the two Banks we are unable to consider the above amount of Tk. 69,28,300 as cash and cash equivalent.

11. Issued, Subscribed and Paid up Capital:	218,009	218,009
Authorized Capital:		
50,000,000 Ordinary Shares @ Tk. 10.00 each	500,000,000	500,000,000
Issued, Subscribed and Paid up Capital:		
6,000,000 Ordinary Shares @ Tk. 10.00 each fully paid-up in cash	60,000,000	60,000,000
600,000 Bonus Shares @ Tk. 10.00 each for the year 2003-2004	6,000,000	6,000,000
990,000 Bonus Shares @ Tk. 10.00 each for the year 2008-2009	9,900,000	9,900,000
1,214,400 Bonus Shares @ Tk. 10.00 each for the year 2010-2011	12,144,000	12,144,000
1,584,792 Bonus Shares @ Tk. 10.00 each for the year 2011-2012	15,847,920	15,847,920
3,116,757 Bonus Shares @ Tk. 10.00 each for the year 2012-2013	31,167,570	31,167,570
1,350,594 Bonus Shares @ Tk. 10.00 each for the year 2013-2014	13,505,940	13,505,940
1,485,654 Bonus Shares @ Tk. 10.00 each for the year 2015-2016	14,856,540	14,856,540
1,634,219 Bonus Shares @ Tk. 10.00 each for the year 2016-2017	16,342,190	16,342,190
898,820 Bonus Shares @ Tk. 10.00 each for the year 2018-2019	8,988,200	8,988,200
943,761 Bonus Shares @ Tk. 10.00 each for the year 2021-2022	9,437,610	9,437,610
19,81,900 Bonus Shares @ Tk. 10.00 each for the year 2022-2023	19,819,000	19,819,000
Total: 2,18,00,897 shares @ Tk. 10.00 each	218,008,970	218,008,970
12. Retained Earnings		
Opening Balance	112,880	121,110
Less: Transfer to Share Capital	-	19,819
	112,880	101,291
Add: Total Comprehensive Income for the year	5,445	12,199
	118,325	113,490
Less: Transferred to Dividend Equalisation Fund	272	610
	118,052	112,880
13. Dividend Equalisation Fund:		
Opening	3,565	2,955
Add: Addition	272	610
Closing	3,837	3,565

	As at September, 30 2024	As at June, 30 2024
Figure in Taka"000"		
14. Revaluation Reserve		
Opening Balance	717,969	636,826
Add: Revaluation gain of land	-	124,099
Less: Transferred to Deferred tax Liabilities (note 14.01)	-	42,956
	717,969	717,969
14.01. Movement in deferred tax liability		
Closing Balance	70,748	70,748
Opening Balance	70,748	27,792
	-	42,956
15. Deferred Tax Liabilities		
Opening Balance	84,953	43,051
Add: Provision made during the year for temporary difference(Note:15.01)	(3,804)	(1,054)
Add: Transferred from Revaluation Reserve (note 14.01)	-	42,956
	81,149	84,953
15.01 Deferred tax liability is arrived at as follows :		
i. Deferred tax on PPE		
Carrying amount (Accounting base)	309,691	311,024
Carrying amount (Tax base)	262,253	247,071
Taxable/(deductible) temporary difference	47,438	63,953
Permanent differences	415	415
Net Taxable/(deductible) temporary difference	47,023	63,538
Deferred tax Liability/(Assets) @ 22.50%	10,580	14,296
ii. Deferred tax on Right of Use Assets		
Carrying amount (Accounting base)	399	798
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	399	798
Deferred tax Liability/(Assets) @ 22.50%	90	180
iii. Deferred tax on Lease Liabilities		
Carrying amount (Accounting base)	-	-
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	-	-
Deferred tax Liability/(Assets) @ 22.50%	-	-
iv. Deferred tax on share of profit on Investments		
Carrying amount (Accounting base)	5,993	5,985
Carrying amount (Tax base)	7,335	7,335
Taxable/(deductible) temporary difference	(1,342)	(1,350)
Deferred tax Liability/(Assets) @ 20%	(268)	(270)
v. Deferred tax on revaluation of property, plant and equipment:		
Carrying amount (Accounting base)	884,345	884,345
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	884,345	884,345
Deferred tax Liability/(Assets) @ 8%	70,748	70,748
Total deferred tax liability as on Sept 30, 2024	81,149	84,953
Movement of Deferred Tax on PL Items		
Opening Deferred Tax Liability	14,206	15,260
Expense/(Income) during the year	(3,804)	(1,054)
Closing Deferred Tax Liability	10,402	14,206
16 Lease Liability		
Opening Balance	890	2,556
Addition during the year	-	-
Finance costs during the year	14	149
Payments during the year	(454)	(1,815)
Closing Liability	450	890

	As at September, 30 2024	As at June, 30 2024
Figure in Taka"000"		
16.01 Lease Liability		
Lease Liability-Current	450	890
Lease Liability-Non Current	-	-
	<u>450</u>	<u>890</u>
17. Long Term Loan		
a. Principal Amount		
Opening Balance	21,741	39,773
Add: Addition during the year	-	-
	<u>21,741</u>	<u>39,773</u>
Less: Repayment	4,680	18,032
Total	<u>17,061</u>	<u>21,741</u>
b. Interest Amount		
Opening Balance	-	-
Add: Addition during the year	690	3,412
	<u>690</u>	<u>3,412</u>
Less: Repayment	690	3,412
Total	<u>-</u>	<u>-</u>
Closing Balance	<u>17,061</u>	<u>21,741</u>
Less: Long Term Loan (Current Portion)	16,800	21,480
Total	<u>261</u>	<u>261</u>
All fixed and floating assets are mortgaged against long term loan.		
18. Trade Payable:		
Advance Receipt from Patient	2,319	2,183
Advance Receipt from rental building	152	152
Current Liability for Expenses	1,137	677
Current Liabilities for Supply	12,388	14,885
Workers profit participation fund (note 18.01)	16,748	16,618
	<u>32,744</u>	<u>34,515</u>
18.01. Workers profit participation fund :		
Opening Balance	16,618	13,973
Less: Paid During the year	-	77
	<u>16,618</u>	<u>13,896</u>
Add: Provision made during the year	130	846
Add: Interest Charged for the year	-	1,876
	<u>16,748</u>	<u>16,618</u>
19. Long Term Loan (Current Portion)		
Closing Balance	<u>16,800</u>	<u>21,480</u>
20. Other Payables		
Withholding Vat Payable	1094	392
Withholding Tax Payable	1670	399
	<u>2,764</u>	<u>791</u>
21. Provision & Accruals:		
Utility Bills	1,989	1,912
Salary & Allowance	8,912	8,760
Others	689	303
	<u>11,590</u>	<u>10,975</u>

	As at September, 30 2024	As at June, 30 2024
Figure in Taka"000"		
22. Provision for Income Taxes		
Opening Balance	8,472	5,353
Less: Adjusted during the year (Note-9)	-	2,651
	8,472	2,702
Less: Paid During the Year	-	-
	8,472	2,702
Add: Provision made during the year	957	5,770
	<u>9,429</u>	<u>8,472</u>

23. Unclaimed Dividend

Opening Balance	1,279	973
Add : Addition during the year	-	307
	1,279	1,280
Less: Capital Market Stabilization Fund	-	-
Less: Paid during the year	-	1
	<u>1,279</u>	<u>1,279</u>

The Above amount of Tk.10,09,218 has been unclaimed for the financial year 2020-2021. As per BSEC Directive No. BSEC/CMRRCD/2021-386/03 dt. January 14, 2021 the amount shall be payable to CMFS as soon as the expiry of 3 years. Hence the amount shall be payable to CMSF on 29th December, 2024.

	September, 30 2024	September, 30 2023
Figure in Taka"000"		
24. Share of Profit / (loss) of Associate :		
Net profit/ (loss) of Associate company	18	44
Share of Profit/ (loss) of Associate company (45% of Tk.18,000)	8	20

25. Revenue

Medical Services	43,899	55,511
Diagnostic	24,589	32,720
Pharmacy	27,644	31,116
	<u>96,132</u>	<u>119,347</u>

26. Direct Expenses:

Medical Services	9,392	8,835
Diagnostic	9,872	11,526
Pharmacy	21,675	22,840
	<u>40,939</u>	<u>43,201</u>

	September, 30 2024	September, 30 2023
Figure in Taka"000"		
27. Administrative Expenses:		
Salary & Allowance	28,108	26,716
Managing Director's Salary	2,061	2,079
Utility Bills	5,967	6,354
Repair	1,641	1,186
Depreciation	5,593	5,673
Depreciation on Right of Use Assets	399	399
Printing	448	716
Bad debt	149	287
Others	8,513	8,641
	52,879	52,051
28. Financial Expenses		
Interest on Term Loan	690	947
Interest on Lease Liability	14	51
	704	998
29. Non Operating Income		
Rent Received	811	804
FDR Interest	45	438
Referral Income	164	164
Others	90	60
	1,110	1,466
30. Current year's Tax	957	5,782
i. Regular Tax		
Net profit before tax as per profit & loss Account	2,598	23,411
Less: Profit/(Loss) from Investments	8	20
	2,590	23,392
Add: Items of charges to be considered separately:		
Accounting depreciation	5,593	5,673
Depreciation on RoU Assets	399	399
Finance Cost on Lease Liabilities	14	51
	6,006	6,123
Less: Admissible items:		
Payments for Leases	454	454
Tax depreciation	3,888	3,362
	4,342	3,816
Total business income during the year	4,254	25,699
Regular Tax on business income @ 22.5%	957	5,782
	957	5,782

31. Special disclosure as per notification No. BSEC/CMRRCD/2006-158/208/Admin/81 is as under:

a) Detailed break-up of shareholders equity:

	As at September, 30 2024	Figure in Taka"000"	As at June, 30 2024
Share Capital	218,009		218,009
Retained Earnings	118,052		112,880
Revaluation Reserve	717,969		717,969
Dividend Equalisation Fund	3,837		3,565
Total Equity	1,057,868		1,052,423

b) Net Asset Value Per Share (NAV)

Total Assets	1,214,332	1,216,039
Less Total liabilities :	156,465	163,616
Non Current Liabilities	81,410	85,214
Current Liabilities	75,055	78,402
Net Assets:	1,057,866	1,052,423
Number of outstanding shares at the year end	21,801	21,801
Net Asset Value Per Share (NAV)	48.52	48.27

c) Basic and diluted Earnings Per Share:

Basic Earning Per Share:

	September, 30 2024	Figure in Taka"000"	September, 30 2023
Profit Attributable to ordinary shareholders	5,445		18,236
Number of outstanding shares at the year end	21,801		21,801
Basic Earning per Share (EPS)	0.25		0.84

Diluted Earning Per Share:

Diluted EPS is determined by adjusting the Profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant period.

d) Net operating cash flows per share (NOCFPS)

Net Cash from Operating Activities	11,529	39,774
Number of outstanding shares at the year end	21,801	21,801
Net operating cash flows per share (NOCFPS)	0.53	1.82

e) Reconciliation of Net profit with Cash Flows from Operating Activities

For the 1st Quarter ended September 30, 2024

Particulars	September, 30 2024	Figure in Taka"000"	September, 30 2023
Profit Before Tax	2,598		23,412
Depreciation	5,992		6,072
Bad debt	149		287
FDR Interest	(45)		(438)
Investment Income (Share of (Profit) /Loss of Associate)	(8)		(20)
Financial Charges	704		998
Payment for lease	(454)		(454)
(Increase)/Decrease in Inventories	551		1,316
(Increase)/Decrease in Trade and other receivable	(596)		(5,066)
(Increase)/Decrease in Advance, Deposits & Prepayment	2,033		1,286
Increase/(Decrease) in Trade Payable	(1,904)		5,164
Increase/(Decrease) in other Payable	1,973		1,285
Increase/(Decrease) in Provision & accruals	466		4,885
Increase/(Decrease) in WPPF	130		1,172
Cash Flows from operation	11,589		39,899
Tax Paid	(60)		(125)
	11,529		39,774

32. Related Party Disclosures (IAS-24):

as on 30th September 2024 (Figure in Taka "000")

SL.No	Particulars	Nature of Relation	Basis of Transactions	Total Transaction Value	Outstanding
1.00	Nurse Hostel	Mrs. Latifa Haroon, W/O Dr.A B M Haroon	Rent paid as per contract	413	-
2.00	The Imaging Services Ltd.	Associate company	Rent as per contract	260	239
			Others as per contract	90	60
3.00	Purabi General Insurance Company Limited	Common director	Insurance Premium paid as per contract	83	-
4.00	M.H. Samorita Hospital & Medical College	Common director	Pathology Test as per negotiation	467	1,283

September, 30 2024	June, 30 2024
-----------------------	------------------

Figure in Taka"000"

33. Disclosure of key management personnel compensation:

Detailed disclosure regarding the compensation packages of key management personnel is presented below.

Key management are those persons having authority and responsibility for planning, Directing and controlling the activities of the company.

i) Remuneration and Meeting fees for Non-executive directors

Remuneration & Other benefits
Board meeting fees

-	-
128	536
128	536

ii) Compensation of key management personnel

- a) Short-term employee benefits
b) Post-employment benefits
c) Other long-term benefits
d) Termination benefits
e) Share-based payment

4,302	17,061
-	-
-	-
-	-
-	-
4,302	17,061

Short term employee benefits consisted of salary, bonus, medical allowance, housing, cars, fees or subsidized goods or services for key management personnel.

Key management personnel includes Managing Director, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance, Head of Administration and Human Resources and Chief Medical Officer.


C F O


Company Secretary


Managing Director


Director


Chairman